Cognitive dysfunction is sustained after rescue therapy in experimental cerebral malaria, and is reduced by additive antioxidant therapy. - Wikidata - awgldk - TriplyDB

Cognitive dysfunction is sustained after rescue therapy in experimental cerebral malaria, and is reduced by additive antioxidant therapy.

Cognitive dysfunction is sustained after rescue therapy in experimental cerebral malaria, and is reduced by additive antioxidant therapy.

http://www.wikidata.org/entity/Q33619092

about

The role of Nox2-derived ROS in the development of cognitive impairment after sepsis Testing in mice the hypothesis that melanin is protective in malaria infections CD19(+) B cells confer protection against experimental cerebral malaria in semi-immune rodent model A rapid murine coma and behavior scale for quantitative assessment of murine cerebral malaria Nitric oxide synthase dysfunction contributes to impaired cerebroarteriolar reactivity in experimental cerebral malaria Statins decrease neuroinflammation and prevent cognitive impairment after cerebral malaria Glucocorticosteroids in nano-sterically stabilized liposomes are efficacious for elimination of the acute symptoms of experimental cerebral malaria Glucagon-like peptide-1 analogue, liraglutide, in experimental cerebral malaria: implications for the role of oxidative stress in cerebral malaria Toxoplasma gondii upregulates interleukin-12 to prevent Plasmodium berghei-induced experimental cerebral malaria.Nitrone-based therapeutics for neurodegenerative diseases: their use alone or in combination with lanthionines.Tempol, an intracellular antioxidant, inhibits tissue factor expression, attenuates dendritic cell function, and is partially protective in a murine model of cerebral malaria.IL-33 receptor ST2 regulates the cognitive impairments associated with experimental cerebral malaria Reduction of experimental cerebral malaria and its related proinflammatory responses by the novel liposome-based β-methasone nanodrug.Persistent cognitive and motor deficits after successful antimalarial treatment in murine cerebral malaria The plant-based immunomodulator curcumin as a potential candidate for the development of an adjunctive therapy for cerebral malaria PPARγ agonists improve survival and neurocognitive outcomes in experimental cerebral malaria and induce neuroprotective pathways in human malaria.N-acetyl cysteine and mushroom Agaricus sylvaticus supplementation decreased parasitaemia and pulmonary oxidative stress in a mice model of malaria.Synthesis of artemiside and its effects in combination with conventional drugs against severe murine malaria Effect of mushroom Agaricus blazei on immune response and development of experimental cerebral malaria.IFN-γ-producing CD4+ T cells promote experimental cerebral malaria by modulating CD8+ T cell accumulation within the brain.Pathogenesis of cerebral malaria: new diagnostic tools, biomarkers, and therapeutic approaches.A quantitative brain map of experimental cerebral malaria pathology.Erythropoietin treatment alleviates ultrastructural myelin changes induced by murine cerebral malaria.The novel ETA receptor antagonist HJP-272 prevents cerebral microvascular hemorrhage in cerebral malaria and synergistically improves survival in combination with an artemisinin derivative Integrin αDβ2 (CD11d/CD18) mediates experimental malaria-associated acute respiratory distress syndrome (MA-ARDS).Transdermal glyceryl trinitrate as an effective adjunctive treatment with artemether for late-stage experimental cerebral malaria.Further evidence for an anti-inflammatory role of artesunate in experimental cerebral malaria Antioxidant potential of a polyherbal antimalarial as an indicator of its therapeutic value.Cerebral malaria pathogenesis: revisiting parasite and host contributions.Host matrix metalloproteinases in cerebral malaria: new kids on the block against blood-brain barrier integrity?The role of antioxidants treatment on the pathogenesis of malarial infections: a review.Cerebral malaria--clinical manifestations and pathogenesis.Controlled release of artemisone for the treatment of experimental cerebral malaria.A Neuroprotective Effect of the Glutamate Receptor Antagonist MK801 on Long-Term Cognitive and Behavioral Outcomes Secondary to Experimental Cerebral Malaria.The intensive care delirium research agenda: a multinational, interprofessional perspective.Artemether and artesunate show the highest efficacies in rescuing mice with late-stage cerebral malaria and rapidly decrease leukocyte accumulation in the brain.Antiplasmodial alkaloids from the bark of Cryptocarya nigra (Lauraceae).Targeting the master regulator mTOR: a new approach to prevent the neurological of consequences of parasitic infections?Cerebral malaria induces electrophysiological and neurochemical impairment in mice retinal tissue: possible effect on glutathione and glutamatergic system.Persistent cognitive impairment after cerebral malaria: models, mechanisms and adjunctive therapies.

P2860

Q21245247-4BD4E62E-6C3A-4DDF-89F8-D4D95C48E24B Q27310640-F49B5AE5-9E99-4D58-8209-BE026B75A40A Q27318165-DE55BBD9-647E-4747-B46C-1A1AF7F875E6 Q27318676-B59ADEB5-D04C-44B8-86CF-6FB0B19AA37B Q27334444-42E2B44B-7E29-479B-A69E-B214091816E2 Q27338288-70654016-6387-4A0B-87C9-7B293616AA4F Q28535601-63A6A6CB-7217-4E86-93B8-FAB1E9A395A8 Q28597322-F99E62E0-F361-4424-817C-1854154CA5F5 Q30411019-FFCB165A-5F9D-435E-BCDA-C0DEE06FA78A Q30431810-B90E63A4-BE15-4568-92C5-76CD18CE542E Q30457536-3CF3AF96-05AF-4C4B-BA46-6402883053A9 Q33610655-20EB02B6-AA60-4BEC-9C6F-15E58AE9FE06 Q34003170-87A20BDE-8E1F-40D4-9EB4-83D0B5D97C15 Q34623145-5DE5DC1F-7626-4421-AF07-F0D83972F45C Q34687796-8C663840-D033-4189-95B6-5CCBD8F7C4AE Q35113069-3FCD9708-5555-444D-9ABB-B757E3A432D8 Q35619602-E3D5CE13-FEC5-48B3-9736-8D7303F26BB5 Q35666544-C0CDDF3D-D56B-4A36-B199-39607530870C Q35936696-B19EB382-9E05-41B0-84BD-96DDE46D9CCE Q36086895-F9162D2C-FD76-4B17-B409-342DF366F4BD Q36209383-2FAF39D7-EA49-4E9E-9CBC-DA523F531A94 Q36300874-7245120E-C2BC-40DC-9682-A8F7CF81B7C2 Q36411555-978162A9-55DB-4288-8F99-959C3DCF237B Q36471393-99D9179C-2640-452D-8B19-AD3508DE4F9F Q37139922-18AF15C3-258C-4F6F-9C42-313A8262F720 Q37263464-D8D4F8DF-1A00-492D-BDF8-A2EA5D70C2B3 Q37306230-21D1E4D7-3EB3-4852-95AF-18F0BB5A5E87 Q37433146-264F2C25-41B1-4DC1-ABF2-D828886BDD96 Q37983138-3600844C-44BB-47B5-83E6-6F5DD2CDD1B9 Q38182192-0A3CBF2D-F53E-4B12-BE48-F71738225DCA Q38187860-0A52E3F0-96F9-4B95-92BC-776A41E4BA3E Q38690668-5FF05530-3B4D-46D5-A9AA-7E13CBEF06C8 Q38935293-6B7FB414-CE47-4D4F-B9B4-F6DB9979B790 Q38966356-888E2284-4876-48CC-8994-0C5739F6E591 Q39371231-A62EC018-4788-48A9-AF1A-3E5AF8081A63 Q42706335-8493F4FE-21DA-4259-8B66-A1B9B012FE43 Q44784711-1CA9DE14-2076-454D-8818-B68A9B60C68F Q45840900-80BD6A84-4C75-44B2-9490-A8758958D811 Q47115445-6AEF40CF-BF1E-4773-9FBB-FCCF2A1C032D Q47965516-FC12379B-2608-4F7F-A9D9-D81D5DE15475

P2860

Cognitive dysfunction is sustained after rescue therapy in experimental cerebral malaria, and is reduced by additive antioxidant therapy.

http://www.wikidata.org/entity/Q33619092

description

2010 nî lūn-bûn

@nan

2010 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Cognitive dysfunction is susta ...... additive antioxidant therapy.

@ast

Cognitive dysfunction is susta ...... additive antioxidant therapy.

@en

type

label

Cognitive dysfunction is susta ...... additive antioxidant therapy.

@ast

Cognitive dysfunction is susta ...... additive antioxidant therapy.

@en

prefLabel

Cognitive dysfunction is susta ...... additive antioxidant therapy.

@ast

Cognitive dysfunction is susta ...... additive antioxidant therapy.

@en

P1433

Q33619092-C71AF81D-2512-429D-B5F8-0AB526F113A9

P1476

Q33619092-A1B949DA-899E-4066-A777-F3301BCA7E65

P2093

Q33619092-059365EB-2DD4-4AEC-A8EE-118BDE3BB357

Q33619092-3162BE54-437D-4AD9-B45C-37B62E1090A4

Q33619092-3989884E-8250-41FE-945A-211A5E1E99DC

Q33619092-44463A56-374A-4AAB-A8AA-966E992F1C86

Q33619092-51E6FA44-A7D9-41D2-A412-E458DE023341

Q33619092-5B7D76BD-43E5-40D5-8E67-C3249BE94FD0

Q33619092-5D02CB08-055C-4E39-A361-4EA9C7ED8171

Q33619092-62AA667C-BFD5-4045-B8BA-3A7AFED93E7B

Q33619092-68196740-3E07-401B-BE99-6502F331E98D

Q33619092-BEF3191F-7097-45FD-B593-EC028035A633

P2860

Q33619092-020C212E-7E3F-48CA-8E2A-5387579C7326

Q33619092-042BE19B-46D9-49EA-95AB-40433308FCA6

Q33619092-0A1BB867-D97C-4B78-876A-8B12C23E5675

Q33619092-0C352E53-C8D2-448B-A325-C3093FEC6504

Q33619092-0D7BC447-1E47-4CAE-BCA1-B88AD5992CE4

Q33619092-0DBB7098-FEAE-4AEA-9EB1-219BA80C145E

Q33619092-10BFB12E-90F3-4785-8E53-23C4B9F14AF1

Q33619092-1111628C-98BE-4ABD-BEDF-BC3D5B6CA956

Q33619092-146A75CA-7909-438E-AF14-35CD598692E8

Q33619092-1648128A-F5F0-4785-9313-64195490174D

P304

Q33619092-7968B9E8-3977-4350-9C04-EAFA2EAD2A76

P31

Q33619092-344DEF9D-1099-46D3-8C2A-89F3BFD34906

P356

Q33619092-306D79EA-C014-4C32-AD4B-D84739DB81C5

P433

Q33619092-47934BEA-08E4-470C-86B5-72108DD72F5B

P478

Q33619092-D90E4181-33E9-4D00-8C06-8487964A3580

P50

Q33619092-4E641435-8D9E-4E8F-BDA9-258B2DB68D07

Q33619092-500FE21F-9212-43F5-B60A-7265160868F6

Q33619092-5A2BC5FB-A111-40CC-99D0-FB02885C8F9A

Q33619092-8093651E-F0AF-4C23-98B1-F4A97A69A4A8

Q33619092-D8CC2036-320C-4654-B7F2-1BF9808DB997

P577

Q33619092-B879A8CE-E73A-49B4-888E-5562BF5DD92F

P5875

Q33619092-B6C35317-BA38-4B85-8A83-9A8333805936

P698

Q33619092-EAA43F2A-1820-407C-8802-D35037F7389F

P921

Q33619092-07099679-47F4-443D-B56B-F306E8E92DAB

Q33619092-1224B080-3487-4C4B-8E3F-3A3B4DDCE9A7

P932

Q33619092-37F0FC58-B0E6-4F5A-86F3-CE36AC7FDE09

P356

JOURNAL.PPAT.1000963

P1433

P1476

Cognitive dysfunction is susta ...... additive antioxidant therapy.

@en

P2093

Aline C Portella

http://www.w3.org/2001/XMLSchema#string

Bruno Silva

http://www.w3.org/2001/XMLSchema#string

Clarissa M Comim

http://www.w3.org/2001/XMLSchema#string

Felipe Dal-Pizzol

http://www.w3.org/2001/XMLSchema#string

Fernanda Hermani

http://www.w3.org/2001/XMLSchema#string

Flavia C A Gomes

http://www.w3.org/2001/XMLSchema#string

Guy A Zimmerman

http://www.w3.org/2001/XMLSchema#string

Hugo C Castro-Faria-Neto

http://www.w3.org/2001/XMLSchema#string

Ive M Sab

http://www.w3.org/2001/XMLSchema#string

Patricia A Reis

http://www.w3.org/2001/XMLSchema#string

P2860

Plasmodium yoelii 17XL infection up-regulates RANTES, CCR1, CCR3 and CCR5 expression, and induces ultrastructural changes in the cerebellum

Memory dysfunction

Memory formation: the sequence of biochemical events in the hippocampus and its connection to activity in other brain structures

Mechanisms for memory types differ

Oxidative stress and neurodegeneration: where are we now?

Common strategies to prevent and modulate experimental cerebral malaria in mouse strains with different susceptibilities.

Gaps in the childhood malaria burden in Africa: cerebral malaria, neurological sequelae, anemia, respiratory distress, hypoglycemia, and complications of pregnancy.

Phagocyte-derived reactive oxygen species do not influence the progression of murine blood-stage malaria infections

Rodent malarias: the mouse as a model for understanding immune responses and pathology induced by the erythrocytic stages of the parasite.

Behavioral and functional analysis of mouse phenotype: SHIRPA, a proposed protocol for comprehensive phenotype assessment.

P304

e1000963

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PPAT.1000963

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

6

http://www.w3.org/2001/XMLSchema#string

P50

Patricia T. Bozza

Marcus Fernandes Oliveira

Tatiana Barichello

Fernando A Bozza

P577

2010-06-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

44807263

http://www.w3.org/2001/XMLSchema#string

P698

20585569

http://www.w3.org/2001/XMLSchema#string

P921

cerebral malaria

P932

2891838

http://www.w3.org/2001/XMLSchema#string